Nassim Usman, CEO, Catalyst Biosciences discusses the problem of Hemophilia, a rare disease in which patients have a genetic deficiency in their ability to prevent bleeding.  Currently, these patients must receive cumbersome bi-weekly IV infusions of clotting factor replacement therapy and may still bleed.  Catalyst is developing a solution to give these patients a better and more convenient treatment particularly for inhibitor patients who have developed antibodies to their replacement therapy. @catalystbio #hemophilia  #catalystbio  #subQ  #biotech Catalyst Biosciences Download the transcript here.